Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Tuberculosis

  Free Subscription


Articles published in Clin Infect Dis

Retrieve available abstracts of 139 articles:
HTML format
Text format



Single Articles


    April 2017
  1. PHILLIPS PP
    Setting tuberculosis regimen development on a firm foundation.
    Clin Infect Dis. 2017 Apr 10. doi: 10.1093.
    PubMed     Text format    


  2. BONNETT LJ, Ken-Dror G, Koh G, Davies GR, et al
    Comparing the efficacy of drug regimens for pulmonary tuberculosis: meta-analysis of endpoints in early phase clinical trials.
    Clin Infect Dis. 2017 Apr 10. doi: 10.1093.
    PubMed     Text format     Abstract available


  3. RAOULT D
    Old Antibiotics for Tuberculosis.
    Clin Infect Dis. 2017;64:983.
    PubMed     Text format    


  4. BROGER T, Basu Roy R, Filomena A, Greef CH, et al
    Diagnostic Performance of Tuberculosis-Specific IgG Antibody Profiles in Patients with Presumptive Tuberculosis from Two Continents.
    Clin Infect Dis. 2017;64:947-955.
    PubMed     Text format     Abstract available


    March 2017
  5. MARKS SM, Mase SR, Bamrah Morris S
    Systematic Review, Meta-Analysis, and Cost Effectiveness of Treatment of Latent Tuberculosis Infection to Reduce Progression to Multidrug-Resistant Tuberculosis.
    Clin Infect Dis. 2017 Mar 14. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2017
  6. ROCKWOOD N N, Pasipanodya JG, Denti P, Sirgel F, et al
    Concentration-dependent antagonism and culture conversion in pulmonary tuberculosis.
    Clin Infect Dis. 2017 Feb 16. doi: 10.1093.
    PubMed     Text format    


  7. COWAN JF, Chandler AS, Kracen E, Park DR, et al
    Clinical Impact and Cost-effectiveness of Xpert MTB/RIF Testing in Hospitalized Patients With Presumptive Pulmonary Tuberculosis in the United States.
    Clin Infect Dis. 2017;64:482-489.
    PubMed     Text format    


  8. JOHNSTON JC, Campbell JR, Menzies D
    Effect of intermittency on treatment outcomes in pulmonary tuberculosis: an updated systematic review and meta-analysis.
    Clin Infect Dis. 2017 Feb 14. doi: 10.1093.
    PubMed     Text format    


  9. JACOBSON KR, Barnard M, Kleinman MB, Streicher EM, et al
    Implications of failure to routinely diagnose resistance to second-line drugs in patients with rifampicin-resistant tuberculosis on Xpert MTB/RIF: a multisite observational study.
    Clin Infect Dis. 2017 Feb 12. doi: 10.1093.
    PubMed     Text format    


    January 2017
  10. PROANO A, Bravard MA, Lopez JW, Lee GO, et al
    Dynamics of Cough Frequency in Adults Undergoing Treatment for Pulmonary Tuberculosis.
    Clin Infect Dis. 2017 Jan 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  11. LEWINSOHN DM, Leonard MK, LoBue PA, Cohn DL, et al
    Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children.
    Clin Infect Dis. 2017;64:111-115.
    PubMed     Text format     Abstract available


    December 2016
  12. LEE MR, Huang YP, Kuo YT, Luo CH, et al
    Diabetes mellitus and latent tuberculosis infection: a systemic review and meta-analysis.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  13. CHENG MP, Abou Chakra CN, Yansouni CP, Cnossen S, et al
    Risk of Active Tuberculosis in Patients with Cancer: A Systematic Review and Meta-Analysis.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  14. CHENG MP, Chakra CN, Yansouni CP, Cnossen S, et al
    Risk of Active Tuberculosis in Patients With Cancer: A Systematic Review and Metaanalysis.
    Clin Infect Dis. 2016 Dec 13. doi: 10.1093.
    PubMed     Text format    


  15. COWAN JF, Chandler AS, Kracen E, Park DR, et al
    Clinical Impact and Cost-Effectiveness of Xpert MTB/RIF Testing in Hospitalized Patients with Presumptive Pulmonary Tuberculosis in the United States.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  16. LEWINSOHN DM, Leonard MK, LoBue PA, Cohn DL, et al
    Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  17. VINNARD C, King L, Munsiff S, Crossa A, et al
    The Long-Term Mortality of Tuberculosis Meningitis Patients in New York City: A Cohort Study.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    November 2016
  18. GUMBO T, Makhene MK, Seddon JA
    Partnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road Ahead.
    Clin Infect Dis. 2016;63.
    PubMed     Text format     Abstract available


  19. SRIVASTAVA S, Deshpande D, Pasipanodya J, Nuermberger E, et al
    Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.
    Clin Infect Dis. 2016;63.
    PubMed     Text format     Abstract available


  20. DESHPANDE D, Srivastava S, Nuermberger E, Pasipanodya JG, et al
    A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.
    Clin Infect Dis. 2016;63.
    PubMed     Text format     Abstract available


  21. DESHPANDE D, Srivastava S, Nuermberger E, Pasipanodya JG, et al
    Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.
    Clin Infect Dis. 2016;63.
    PubMed     Text format     Abstract available


  22. DESHPANDE D, Srivastava S, Pasipanodya JG, Bush SJ, et al
    Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps.
    Clin Infect Dis. 2016;63.
    PubMed     Text format     Abstract available


  23. SRIVASTAVA S, Deshpande D, Pasipanodya JG, Thomas T, et al
    A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground.
    Clin Infect Dis. 2016;63.
    PubMed     Text format     Abstract available


  24. SWAMINATHAN S, Pasipanodya JG, Ramachandran G, Hemanth Kumar AK, et al
    Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests.
    Clin Infect Dis. 2016;63.
    PubMed     Text format     Abstract available


  25. SEDDON JA, Makhene MK
    Harnessing Novel Quantitative Pharmacology Approaches to Optimize the Treatment of Children With Tuberculosis.
    Clin Infect Dis. 2016;63.
    PubMed     Text format    


    October 2016
  26. ALFFENAAR JC, Tiberi S, Verbeeck RK, Heysell SK, et al
    Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  27. NAHID P, Dorman SE, Alipanah N, Barry PM, et al
    Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.
    Clin Infect Dis. 2016;63:853-67.
    PubMed     Text format     Abstract available


    September 2016
  28. YANG JY, Han M, Koh Y, Kim WS, et al
    Effects of Corticosteroids on Critically Ill Pulmonary Tuberculosis Patients with Acute Respiratory Failure: A Propensity Analysis of Mortality.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    August 2016
  29. NAHID P, Dorman SE, Alipanah N, Barry PM, et al
    Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    July 2016
  30. CHIANG SS, Starke JR, Miller AC, Cruz AT, et al
    Baseline Predictors of Treatment Outcomes in Children with Multidrug-Resistant Tuberculosis: a Retrospective Cohort Study.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    June 2016
  31. FUJIWARA PI, Olea-Popelka F
    Why it is important to distinguish Mycobacterium bovis as a causal agent of human tuberculosis.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  32. SCOTT C, Cavanaugh JS, Pratt R, Silk BJ, et al
    Human tuberculosis caused by Mycobacterium bovis in the United States, 2006-2013.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  33. LIENHARDT C, Kraigsley AM, Sizemore CF
    Driving the Way to Tuberculosis Elimination: The Essential Role of Fundamental Research.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    May 2016
  34. VON DELFT A, Dramowski A, Sifumba Z, Mosidi T, et al
    Exposed, but Not Protected: More Is Needed to Prevent Drug-Resistant Tuberculosis in Healthcare Workers and Students.
    Clin Infect Dis. 2016;62 Suppl 3:S275-80.
    PubMed     Text format     Abstract available


  35. BOULANGER RF, Hunt MR, Benatar SR
    Where Caring Is Sharing: Evolving Ethical Considerations in Tuberculosis Prevention Among Healthcare Workers.
    Clin Infect Dis. 2016;62 Suppl 3:S268-74.
    PubMed     Text format     Abstract available


  36. HATHERILL M, Scriba TJ, Udwadia ZF, Mullerpattan JB, et al
    BCG and New Preventive Tuberculosis Vaccines: Implications for Healthcare Workers.
    Clin Infect Dis. 2016;62 Suppl 3:S262-7.
    PubMed     Text format     Abstract available


  37. TUDOR C, Van der Walt ML, Margot B, Dorman SE, et al
    Occupational Risk Factors for Tuberculosis Among Healthcare Workers in KwaZulu-Natal, South Africa.
    Clin Infect Dis. 2016;62 Suppl 3:S255-61.
    PubMed     Text format     Abstract available


  38. WOUTERS E, Rau A, Engelbrecht M, Uebel K, et al
    The Development and Piloting of Parallel Scales Measuring External and Internal HIV and Tuberculosis Stigma Among Healthcare Workers in the Free State Province, South Africa.
    Clin Infect Dis. 2016;62 Suppl 3:S244-54.
    PubMed     Text format     Abstract available


  39. VAN CUTSEM G, Isaakidis P, Farley J, Nardell E, et al
    Infection Control for Drug-Resistant Tuberculosis: Early Diagnosis and Treatment Is the Key.
    Clin Infect Dis. 2016;62 Suppl 3:S238-43.
    PubMed     Text format     Abstract available


  40. VERKUIJL S, Middelkoop K
    Protecting Our Front-liners: Occupational Tuberculosis Prevention Through Infection Control Strategies.
    Clin Infect Dis. 2016;62 Suppl 3:S231-7.
    PubMed     Text format     Abstract available


  41. EVANS TG, Bekker LG
    Tuberculosis and Healthcare Workers in Underresourced Settings.
    Clin Infect Dis. 2016;62 Suppl 3:S229-30.
    PubMed     Text format    


  42. DINARDO AR, Lange C, Mandalakas AM
    Editorial Commentary: 1, 2, 3 (Years) ... and You're Out: The End of a 123-year Historic Era.
    Clin Infect Dis. 2016;62:1089-91.
    PubMed     Text format    


    March 2016
  43. JONES-LOPEZ EC, Acuna-Villaorduna C, Ssebidandi M, Gaeddert M, et al
    Cough Aerosols of Mycobacterium tuberculosis Predict Incident Tuberculosis Disease in Household Contacts.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  44. BAHR NC, Marais S, Caws M, van Crevel R, et al
    GeneXpert MTB/Rif to Diagnose Tuberculous Meningitis: Perhaps the First Test but not the Last.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  45. MORO RN, Borisov A, Saukkonen J, Khan A, et al
    Factors Associated with Non-completion of Latent Tuberculosis Infection Treatment: Experience from the PREVENT TB Trial in the United States and Canada.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  46. GARCIA MJ, Lopez MR
    Do we have strategies to improve the preventive treatment of Latent Tuberculosis Infection?
    Clin Infect Dis. 2016.
    PubMed     Text format    


  47. BARNER A, Frank C, Shipton L
    Tooth Discoloration in a Patient With Multidrug-Resistant Tuberculosis.
    Clin Infect Dis. 2016;62:664-5.
    PubMed     Text format    



  48. Tooth Discoloration in a Patient With Multidrug-Resistant Tuberculosis.
    Clin Infect Dis. 2016;62:617.
    PubMed     Text format    


    February 2016
  49. TIBERI S, Sotgiu G, D'Ambrosio L, Centis R, et al
    Comparison of effectiveness and safety of imipenem/clavulanate added to an optimised background regimen (OBR) versus OBR controls regimens in the treatment of multidrug and extensively drug-resistant tuberculosis.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  50. THERON G, Venter R, Calligaro G, Smith L, et al
    Xpert MTB/RIF Results in Patients With Previous Tuberculosis: Can We Distinguish True From False Positive Results?
    Clin Infect Dis. 2016 Feb 16. pii: civ1223.
    PubMed     Text format     Abstract available


  51. DETJEN AK, Walters E
    Improving Children's Access to New Tuberculosis Diagnostic Tools Starts With the Collection of Appropriate Specimens.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  52. MARCY O, Ung V, Goyet S, Borand L, et al
    Performance of Xpert MTB/RIF and Alternative Specimen Collection Methods for the Diagnosis of Tuberculosis in HIV-Infected Children.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  53. FIRNHABER C, Kendall MA, Wu X, Mazurek GH, et al
    Evaluation of Xpert MTB/RIF to identify pulmonary tuberculosis in tuberculosis suspects from low and higher prevalence settings compared to acid fast smear and culture.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    January 2016
  54. SHAH NS, Yuen CM, Heo M, Tolman AW, et al
    Reply to Hong-min et al.
    Clin Infect Dis. 2016;62:267-8.
    PubMed     Text format    


  55. HSU DC, Faldetta KF, Pei L, Sheikh V, et al
    A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS.
    Clin Infect Dis. 2016;62:258-61.
    PubMed     Text format     Abstract available


  56. FOX GJ, Mitnick CD, Benedetti A, Chan ED, et al
    Surgery as an adjunctive treatment for multi-drug resistant tuberculosis: an individual patient data meta-analysis.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    December 2015
  57. GUPTA A, Mathad JS, Abdel-Rahman SM, Albano JD, et al
    Towards Earlier Inclusion of Pregnant and Postpartum Women in TB Drug Trials: Consensus Statements from an International Expert Panel.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  58. XIE YL, Rosen LB, Sereti I, Barber DL, et al
    Severe paradoxical reaction during treatment of disseminated tuberculosis in a patient with neutralizing anti-IFNgamma autoantibodies.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


    November 2015
  59. RAVIMOHAN S, Tamuhla N, Nfanyana K, Steenhoff AP, et al
    Robust reconstitution of TB-specific polyfunctional CD4+ T-cell responses and rising systemic IL-6 in paradoxical TB-IRIS.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  60. AKKERMAN OW, Odish OF, Bolhuis MS, de Lange WC, et al
    Pharmacokinetics of bedaquiline in cerebrospinal fluid and serum in multidrug-resistant tuberculous meningitis.
    Clin Infect Dis. 2015.
    PubMed     Text format    


  61. LANOIX JP, Chaisson RE, Nuermberger EL
    Shortening tuberculosis treatment with fluoroquinolones: lost in translation?
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


    October 2015
  62. CEGIELSKI JP, Kurbatova E, van der Walt M, Brand J, et al
    Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment, Initial and Acquired Second-Line Drug Resistance.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  63. SCHITO M, Maeurer M, Kim P, Hanna D, et al
    Translating the Tuberculosis Research Agenda: Much Accomplished, but Much More to Be Done.
    Clin Infect Dis. 2015;61Suppl 3:S95-S101.
    PubMed     Text format     Abstract available


  64. RAO M, Valentini D, Poiret T, Dodoo E, et al
    B in TB: B Cells as Mediators of Clinically Relevant Immune Responses in Tuberculosis.
    Clin Infect Dis. 2015;61Suppl 3:S225-34.
    PubMed     Text format     Abstract available


  65. MAHON RN, Hafner R
    Immune Cell Regulatory Pathways Unexplored as Host-Directed Therapeutic Targets for Mycobacterium tuberculosis: An Opportunity to Apply Precision Medicine Innovations to Infectious Diseases.
    Clin Infect Dis. 2015;61Suppl 3:S200-16.
    PubMed     Text format     Abstract available


  66. SEDDON JA, McKenna L, Shah T, Kampmann B, et al
    Recent Developments and Future Opportunities in the Treatment of Tuberculosis in Children.
    Clin Infect Dis. 2015;61Suppl 3:S188-99.
    PubMed     Text format     Abstract available


  67. GRAHAM SM, Cuevas LE, Jean-Philippe P, Browning R, et al
    Clinical Case Definitions for Classification of Intrathoracic Tuberculosis in Children: An Update.
    Clin Infect Dis. 2015;61Suppl 3:S179-87.
    PubMed     Text format     Abstract available


  68. ZAR HJ, Workman LJ, Little F, Nicol MP, et al
    Diagnosis of Pulmonary Tuberculosis in Children: Assessment of the 2012 National Institutes of Health Expert Consensus Criteria.
    Clin Infect Dis. 2015;61Suppl 3:S173-8.
    PubMed     Text format     Abstract available


  69. NICOL MP, Gnanashanmugam D, Browning R, Click ES, et al
    A Blueprint to Address Research Gaps in the Development of Biomarkers for Pediatric Tuberculosis.
    Clin Infect Dis. 2015;61Suppl 3:S164-72.
    PubMed     Text format     Abstract available


  70. WALLIS RS, Peppard T
    Early Biomarkers and Regulatory Innovation in Multidrug-Resistant Tuberculosis.
    Clin Infect Dis. 2015;61Suppl 3:S160-3.
    PubMed     Text format     Abstract available


  71. HAMILTON CD, Swaminathan S, Christopher DJ, Ellner J, et al
    RePORT International: Advancing Tuberculosis Biomarker Research Through Global Collaboration.
    Clin Infect Dis. 2015;61Suppl 3:S155-9.
    PubMed     Text format     Abstract available


  72. KNIGHT GM, Colijn C, Shrestha S, Fofana M, et al
    The Distribution of Fitness Costs of Resistance-Conferring Mutations Is a Key Determinant for the Future Burden of Drug-Resistant Tuberculosis: A Model-Based Analysis.
    Clin Infect Dis. 2015;61Suppl 3:S147-54.
    PubMed     Text format     Abstract available


  73. STARKS AM, Aviles E, Cirillo DM, Denkinger CM, et al
    Collaborative Effort for a Centralized Worldwide Tuberculosis Relational Sequencing Data Platform.
    Clin Infect Dis. 2015;61Suppl 3:S141-6.
    PubMed     Text format     Abstract available


  74. LANGLEY I, Squire SB, Dacombe R, Madan J, et al
    Developments in Impact Assessment of New Diagnostic Algorithms for Tuberculosis Control.
    Clin Infect Dis. 2015;61Suppl 3:S126-34.
    PubMed     Text format     Abstract available


  75. DOMINIQUE JK, Ortiz-Osorno AA, Fitzgibbon J, Gnanashanmugam D, et al
    Implementation of HIV and Tuberculosis Diagnostics: The Importance of Context.
    Clin Infect Dis. 2015;61Suppl 3:S119-25.
    PubMed     Text format     Abstract available


  76. SCHITO M, Migliori GB, Fletcher HA, McNerney R, et al
    Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.
    Clin Infect Dis. 2015;61Suppl 3:S102-18.
    PubMed     Text format     Abstract available


    September 2015
  77. HONG-MIN W, Xiao-Hong Z, Jing W
    Drug-resistant tuberculosis and the prevention of ongoing transmission.
    Clin Infect Dis. 2015.
    PubMed     Text format    


  78. STENNIS N, Burzynski J, Herbert C, Nilsen D, et al
    Treatment for tuberculosis infection with three months of rifapentine and isoniazid in New York City Health Department clinics.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


    August 2015
  79. ROMERO K, Clay R, Hanna D
    Strategic Regulatory Evaluation and Endorsement of the Hollow Fiber Tuberculosis System as a Novel Drug Development Tool.
    Clin Infect Dis. 2015;61 Suppl 1:S5-9.
    PubMed     Text format     Abstract available


  80. GUMBO T, Pasipanodya JG, Romero K, Hanna D, et al
    Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.
    Clin Infect Dis. 2015;61 Suppl 1:S25-31.
    PubMed     Text format     Abstract available


  81. GUMBO T, Pasipanodya JG, Nuermberger E, Romero K, et al
    Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.
    Clin Infect Dis. 2015;61 Suppl 1:S18-24.
    PubMed     Text format     Abstract available


  82. PASIPANODYA JG, Nuermberger E, Romero K, Hanna D, et al
    Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.
    Clin Infect Dis. 2015;61 Suppl 1:S10-7.
    PubMed     Text format     Abstract available


  83. CAVALERI M, Manolis E
    Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience.
    Clin Infect Dis. 2015;61 Suppl 1:S1-4.
    PubMed     Text format     Abstract available


    July 2015
  84. TIEN V, Robilotti E, Callister D, Subramanian A, et al
    Tolerability of Fluoroquinolones in Management of Latent Tuberculosis in Liver Transplant Candidates.
    Clin Infect Dis. 2015.
    PubMed     Text format    


  85. DASKAPAN A, Stienstra Y, Akkerman OW, de Lange WC, et al
    The Never Ending Struggle Against Development of Drug Resistance.
    Clin Infect Dis. 2015;61:137-8.
    PubMed     Text format    


  86. NARENDRAN G, Swaminathan S
    Reply to Daskapan et al.
    Clin Infect Dis. 2015;61:138-9.
    PubMed     Text format    


    June 2015
  87. TABURET AM, Sauvageon H, Grinsztejn B, Assuied A, et al
    Pharmacokinetics of Raltegravir in HIV-infected Patients on Rifampicin-Based Antitubercular Therapy.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  88. PODANY AT, Bao Y, Swindells S, Chaisson RE, et al
    Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  89. SHANN F
    Different strains of Bacillus Calmette-Guerin vaccine have very different effects on tuberculosis and on unrelated infections.
    Clin Infect Dis. 2015.
    PubMed     Text format    


  90. BIALVAEI AZ, Kafil HS, Asgharzadeh M
    Role of Treatment Cost on Transmission of Multidrug-Resistant Tuberculosis Into Iran.
    Clin Infect Dis. 2015.
    PubMed     Text format    


    May 2015
  91. ZAVALA S, Seas C, Legua P
    A 55-year-old peruvian woman with unresponsive pulmonary tuberculosis.
    Clin Infect Dis. 2015;60:1582-3.
    PubMed     Text format    



  92. A 55-year-old peruvian woman with unresponsive pulmonary tuberculosis.
    Clin Infect Dis. 2015;60:1532.
    PubMed     Text format    


  93. MAKHARIA GK, Ghoshal UC, Ramakrishna BS, Agnihotri A, et al
    Intermittent supervised therapy for abdominal tuberculosis: A multicenter randomized controlled trial comparing 6 months versus 9 months duration of therapy.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  94. RIBEIRO FK, Pan W, Bertolde A, Vinhas SA, et al
    Genotypic and spatial analysis of Mycobacterium tuberculosis transmission in a high-incidence urban setting.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  95. CHOW FC, Glaser CA, Sheriff H, Xia D, et al
    Use of clinical and neuroimaging characteristics to distinguish temporal lobe herpes simplex encephalitis from its mimics.
    Clin Infect Dis. 2015;60:1377-83.
    PubMed     Text format     Abstract available


    April 2015
  96. JOHANSEN IS, Nielsen SL, Hove M, Kehrer M, et al
    Characteristics and clinical outcome of bone and joint tuberculosis from 1994 to 2011: a retrospective register-based study in Denmark.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  97. STERLING TR, Moro RN, Borisov AS, Phillips E, et al
    Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT TB study.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  98. CHAISSON LH, Davis JL
    Reply to Baker and Holtom.
    Clin Infect Dis. 2015;60:1288-9.
    PubMed     Text format    


  99. BASTOS ML, Menzies D
    Reply to Wang and Zhang.
    Clin Infect Dis. 2015;60:1286-7.
    PubMed     Text format    


    March 2015
  100. AREND SM, van Soolingen D
    Genotyping of Mycobacterium tuberculosis in China and missing links in the chain of ongoing transmission of tuberculosis.
    Clin Infect Dis. 2015.
    PubMed     Text format    


  101. YANG C, Shen X, Peng Y, Lan R, et al
    Transmission of Mycobacterium tuberculosis in China: A population-based molecular epidemiology study.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  102. SHIVAKOTI R, Yang WT, Gupte N, Berendes S, et al
    Concurrent anemia and elevated CRP predicts HIV clinical treatment failure, including TB, post-antiretroviral therapy initiation.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  103. SLOAN DJ, Mwandumba HC, Garton NJ, Khoo SH, et al
    Pharmacodynamic modelling of bacillary elimination rates and detection of bacterial lipid bodies in sputum to predict and understand outcomes in treatment of pulmonary tuberculosis.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  104. KIM SH, Kim MY, Hong SI, Jung J, et al
    Invasive pulmonary aspergillosis-mimicking tuberculosis.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  105. RAOULT D
    Extensively drug-resistant tuberculosis: you can teach an old dog new tricks.
    Clin Infect Dis. 2015;60:971.
    PubMed     Text format    


  106. SOMAN R, Shetty A, Rodrigues C
    We must halt the progression of multidrug-resistant tuberculosis to extensively drug-resistant tuberculosis, no matter what the cost.
    Clin Infect Dis. 2015;60:968.
    PubMed     Text format    


  107. ALFFENAAR JW, Gumbo T, Aarnoutse RE
    Acquired drug resistance: we can do more than we think!
    Clin Infect Dis. 2015;60:969-70.
    PubMed     Text format    


  108. METCALFE JZ, Vittinghoff E, Hopewell PC
    Analysis of Green Light Committee implementation and acquisition of second-line drug resistance.
    Clin Infect Dis. 2015;60:970.
    PubMed     Text format    


    February 2015
  109. LUETKEMEYER AF, Rosenkranz SL, Lu D, Grinsztejn B, et al
    Combined Effect of CYP2B6 and NAT2 Genotype on Plasma Efavirenz Exposure during Rifampin-based Anti-Tuberculosis Therapy in the STRIDE Study.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  110. TORRE-CISNEROS J, Juan RS, Rosso-Fernandez CM, Silva JT, et al
    Tuberculosis prophylaxis with levofloxacin in liver transplant patients is associated with a high incidence of tenosynovitis: Safety analysis of a multicenter randomized trial.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


    January 2015
  111. KERKHOFF AD, Lawn SD
    Iron Replacement Therapy and Anemia Associated with Chronic Infectious Diseases in Sub-Saharan Africa.
    Clin Infect Dis. 2015.
    PubMed     Text format    


  112. TANG S, Yao L, Hao X, Liu Y, et al
    Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  113. BAKER BJ, Holtom PD
    Additional Benefits of GeneXpert MTB/RIF Assay for the Evaluation of Pulmonary Tuberculosis Among Inpatients.
    Clin Infect Dis. 2015.
    PubMed     Text format    


    December 2014
  114. HONG-MIN W, Xiao-Hong Z
    The association of DST results for first- and second-line drugs with treatment outcomes in patients with MDR tuberculosis and XDR tuberculosis.
    Clin Infect Dis. 2014 Dec 30. pii: ciu1169.
    PubMed     Text format    


  115. LAWN SD, Nicol MP
    Dead or Alive: Can Viability Staining Predict Response to Tuberculosis Treatment?
    Clin Infect Dis. 2014 Dec 23. pii: ciu1156.
    PubMed     Text format    


  116. DATTA S, Sherman JM, Bravard MA, Valencia T, et al
    Clinical evaluation of tuberculosis viability microscopy for assessing treatment response.
    Clin Infect Dis. 2014 Dec 23. pii: ciu1153.
    PubMed     Text format     Abstract available


    November 2014
  117. MINCHELLA PA, Donkor S, Owolabi O, Sutherland JS, et al
    Complex anemia in tuberculosis: the need to consider causes and timing while designing interventions.
    Clin Infect Dis. 2014.
    PubMed     Text format     Abstract available


  118. GOLUB JE, Cohn S, Saraceni V, Cavalcante SC, et al
    Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium burden tuberculosis setting: the TB/HIV in Rio (THRio) Study.
    Clin Infect Dis. 2014.
    PubMed     Text format     Abstract available


    October 2014
  119. ROZOT V, Patrizia A, Vigano S, Mazza-Stalder J, et al
    The Combined Use of M. tuberculosis-specific CD4 and CD8 T-Cell Responses Is a Powerful Diagnostic Tool of Active Tuberculosis.
    Clin Infect Dis. 2014.
    PubMed     Text format     Abstract available


  120. THEE S, Garcia-Prats AJ, Draper HR, McIlleron HM, et al
    The pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis.
    Clin Infect Dis. 2014.
    PubMed     Text format     Abstract available


  121. MCMULLEN SE, Pegues DA, Shofer FS, Sheller AC, et al
    Reply to Islam et al and Mendy et al.
    Clin Infect Dis. 2014;59:1189-90.
    PubMed     Text format    


  122. VISSER DH, Solomons RS, Ronacher K, van Well GT, et al
    Host immune response to tuberculous meningitis.
    Clin Infect Dis. 2014.
    PubMed     Text format     Abstract available


    September 2014
  123. DENKINGER CM, Pai M
    Reply to El Sahly.
    Clin Infect Dis. 2014;59:912.
    PubMed     Text format    


    August 2014
  124. NARENDRAN G, Menon PA, Venkatesan P, Vijay K, et al
    Acquired Rifampicin Resistance in Thrice-Weekly TB Therapy: Impact of HIV and Antiretroviral Therapy.
    Clin Infect Dis. 2014.
    PubMed     Text format     Abstract available


  125. SOLOMONS RS, Wessels M, Visser DH, Donald PR, et al
    Uniform research case definition criteria differentiate tuberculous and bacterial meningitis in children.
    Clin Infect Dis. 2014.
    PubMed     Text format     Abstract available


  126. MANGTANI P, Rodrigues LC, Sterne JA, Abubakar I, et al
    Reply to Kernodle and von Reyn.
    Clin Infect Dis. 2014;59:608-9.
    PubMed     Text format    


  127. KERNODLE DS
    Problems with ascribing between-trial differences in BCG effectiveness to sensitization with environmental mycobacteria.
    Clin Infect Dis. 2014;59:605-7.
    PubMed     Text format    


  128. VON REYN CF
    BCG, Latitude, and Environmental Mycobacteria.
    Clin Infect Dis. 2014;59:607-8.
    PubMed     Text format    


  129. MARAIS S, Wilkinson KA, Lesosky M, Coussens AK, et al
    Neutrophil-associated central nervous system inflammation in tuberculous meningitis immune reconstitution inflammatory syndrome.
    Clin Infect Dis. 2014.
    PubMed     Text format     Abstract available


  130. CHAISSON LH, Roemer M, Cantu D, Haller B, et al
    Impact of GeneXpert MTB/RIF on Triage of Respiratory Isolation Rooms for Inpatients with Presumed TB: A Hypothetical Trial.
    Clin Infect Dis. 2014.
    PubMed     Text format     Abstract available


    July 2014
  131. KIM CH, Lee J
    Reply to Hong et al.
    Clin Infect Dis. 2014;59:142-3.
    PubMed     Text format    


    June 2014
  132. SLATER M, Dubose A, Banaei N
    False-positive quantiferon results at a large healthcare institution.
    Clin Infect Dis. 2014;58:1641-2.
    PubMed     Text format    


    April 2014
  133. SOHN H, Aero AD, Menzies D, Behr M, et al
    Xpert MTB/RIF testing in a low tuberculosis incidence, high-resource setting: limitations in accuracy and clinical impact.
    Clin Infect Dis. 2014;58:970-6.
    PubMed     Text format     Abstract available


  134. SALFINGER M
    Molecular laboratory testing for tuberculosis: innovators, early adopters, or laggards?
    Clin Infect Dis. 2014;58:977-9.
    PubMed     Text format    


  135. SYRIGOU E, Gkiozos I, Dannos I, Grapsa D, et al
    Giant tuberculin reaction associated with the homeopathic drug tuberculinum: a case report.
    Clin Infect Dis. 2014;58:e119-21.
    PubMed     Text format     Abstract available


    March 2014
  136. MUNOZ L, Santin M
    Interferon-gamma release assays in solid organ transplant recipients: everything begins with a single small step.
    Clin Infect Dis. 2014;58:904-5.
    PubMed     Text format    


  137. HORNE DJ, Narita M, Spitters CL, Limaye AP, et al
    Reply to Munoz and Santin.
    Clin Infect Dis. 2014;58:905-6.
    PubMed     Text format    


    February 2014
  138. MASUR H, Brooks JT, Benson CA, Holmes K, et al
    Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents--Updated Guidelines from CDC, NIH, and HIVMA of the IDSA.
    Clin Infect Dis. 2014.
    PubMed     Text format     Abstract available


  139. MCSHANE H
    Understanding BCG is the key to improving it.
    Clin Infect Dis. 2014;58:481-2.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: